Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy
Approval based on phase III MAJESTY results demonstrating Gazyva/Gazyvaro superiority over tacrolimus in achieving complete remission of proteinuria…